Data Availability. All data in the paper are included in the dataset of the
that human exposure approaching these levels is exceptionally
unlikely (54).
Materials and Methods
ACKNOWLEDGMENTS. This study was supported by the Japan Society for
the Promotion of Science (JSPS) (to K.H., 17H04243), Japan Agency for
Medical Research and Development (to K.H., JP19dm0107119), the National
Institute of Environmental Health Sciences (NIEHS) River Award R35
ES030443-01 (to B.D.H.), and NIEHS Superfund Program P42 ES004699
(to B.D.H.).
Details of the experimental protocols, including animals, maternal glyph-
osate exposure, measurement of glyphosate in the blood, oxylipin analysis,
Western blot analysis, RT-PCR, behavioral tests, treatment of TPPU, immuno-
histochemistry, measurement of amino acids, gut microbiota analysis, and sta-
1. M. C. Lai, M. V. Lombardo, S. Baron-Cohen, Autism. Lancet 383, 896–910 (2014).
2. C. Lord, M. Elsabbagh, G. Baird, J. Veenstra-Vanderweele, Autism spectrum disorder.
Lancet 392, 508–520 (2018).
3. S. N. Hansen, D. E. Schendel, E. T. Parner, Explaining the increase in the prevalence of
autism spectrum disorders: The proportion attributable to changes in reporting
practices. JAMA Pediatr. 169, 56–62 (2015).
4. J. Baio et al., Prevalence of autism spectrum disorder among children aged 8 years–
autism and developmental disabilities monitoring network, 11 sites, United States,
2014. MMWR Surveill. Summ. 67, 1–23 (2018).
5. J. Hallmayer et al., Genetic heritability and shared environmental factors among twin
pairs with autism. Arch. Gen. Psychiatry 68, 1095–1102 (2011).
6. L. A. Sealey et al., Environmental factors in the development of autism spectrum
disorders. Environ. Int. 88, 288–298 (2016).
7. S. K. Sagiv et al., Prenatal organophosphate pesticide exposure and traits related to
autism spectrum disorders in a population living in proximity to agriculture. Environ.
Health Perspect. 126, 047012 (2018).
8. J. Y. Kim et al., Environmental risk factors and biomarkers for autism spectrum dis-
order: An umbrella review of the evidence. Lancet Psychiatry 6, 590–600 (2019).
9. S. M. Bradberry, A. T. Proudfoot, J. A. Vale, Glyphosate poisoning. Toxicol. Rev. 23,
159–167 (2004).
10. L. D. Kier, D. J. Kirkland, Review of genotoxicity studies of glyphosate and glyphosate-
based formulations. Crit. Rev. Toxicol. 43, 283–315 (2013).
11. A. Samsel, S. Seneff, Glyphosate, pathways to modern diseases II: Celiac sprue and
gluten intolerance. Interdiscip. Toxicol. 6, 159–184 (2013).
12. N. L. Swanson, A. Leu, J. Abrahamson, B. Wallet, Genetically engineered crops,
glyphosate and the deterioration of health in the United States of America. J. Org.
Syst. 9, 6–37 (2014).
13. A. Samsel, S. Seneff, Glyphosate, pathways to modern diseases III: Manganese, neu-
rological diseases, and associated pathologies. Surg. Neurol. Int. 6, 45 (2015).
14. O. S. von Ehrenstein et al., Prenatal and infant exposure to ambient pesticides and
autism spectrum disorder in children: Population based case-control study. BMJ 364,
l962 (2019).
15. M. L. Estes, A. K. McAllister, Maternal immune activation: Implications for neuro-
psychiatric disorders. Science 353, 772–777 (2016).
16. H. Y. Jiang et al., Maternal infection during pregnancy and risk of autism spectrum
disorders: A systematic review and meta-analysis. Brain Behav. Immun. 58, 165–172
(2016).
17. M. Careaga, T. Murai, M. D. Bauman, Maternal immune activation and autism spec-
trum disorder: From rodents to nonhuman and human primates. Biol. Psychiatry 81,
391–401 (2017).
18. O. Zerbo et al., Association between influenza infection and vaccination during
pregnancy and risk of autism spectrum disorder. JAMA Pediatr. 171, e163609 (2017).
19. K. Hashimoto, Recent advances in the early intervention in schizophrenia: Future
direction from preclinical findings. Curr. Psychiatry Rep. 21, 75 (2019).
20. A. S. Brown, U. Meyer, Maternal immune activation and neuropsychiatric illness: A
translational research perspective. Am. J. Psychiatry 175, 1073–1083 (2018).
21. C. Morisseau, B. D. Hammock, Epoxide hydrolases: Mechanisms, inhibitor designs, and
biological roles. Annu. Rev. Pharmacol. Toxicol. 45, 311–333 (2005).
22. J. D. Imig, B. D. Hammock, Soluble epoxide hydrolase as a therapeutic target for
cardiovascular diseases. Nat. Rev. Drug Discov. 8, 794–805 (2009).
23. C. Morisseau, B. D. Hammock, Impact of soluble epoxide hydrolase and epox-
yeicosanoids on human health. Annu. Rev. Pharmacol. Toxicol. 53, 37–58 (2013).
24. K. Hashimoto, Role of soluble epoxide hydrolase in metabolism of PUFAs in psychi-
atric and neurological disorders. Front. Pharmacol. 10, 36 (2019).
25. Q. Ren et al., Gene deficiency and pharmacological inhibition of soluble epoxide
hydrolase confers resilience to repeated social defeat stress. Proc. Natl. Acad. Sci.
U.S.A. 113, E1944–E1952 (2016).
29. Q. Ren et al., Soluble epoxide hydrolase plays a key role in the pathogenesis of
Parkinson’s disease. Proc. Natl. Acad. Sci. U.S.A. 115, E5815–E5823 (2018).
30. M. Ma et al., Key role of soluble epoxide hydrolase in the neurodevelopmental dis-
orders of offspring after maternal immune activation. Proc. Natl. Acad. Sci. U.S.A. 116,
7083–7088 (2019).
31. K. Hashimoto, Understanding the link between maternal infections and neuro-
developmental disorders in offspring: The role of abnormalities in metabolism of
polyunsaturated fatty acids. Brain Behav. Immun. 81, 4–5 (2019).
32. J. Atone, K. Wagner, K. Hashimoto, B. D. Hammock, Cytochrome P450 derived ep-
oxidized fatty acids as a therapeutic tool against neuroinflammatory diseases. Pros-
taglandins Other Lipid Mediat. 147, 106385 (2020).
33. A. Shinohe et al., Increased serum levels of glutamate in adult patients with autism.
Prog. Neuropsychopharmacol. Biol. Psychiatry 30, 1472–1477 (2006).
34. C. Shimmura et al., Alteration of plasma glutamate and glutamine levels in children
with high-functioning autism. PLoS One 6, e25340 (2011).
35. Z. Zheng, T. Zhu, Y. Qu, D. Mu, Blood glutamate levels in autism spectrum disorder: A
systematic review and meta-analysis. PLoS One 11, e0158688 (2016).
36. M. Wang et al., Alterations in gut glutamate metabolism associated with changes in
gut microbiota composition in children with autism spectrum disorder. mSystems 4,
e00321-18 (2019).
37. A. Tomova et al., Gastrointestinal microbiota in children with autism in Slovakia.
Physiol. Behav. 138, 179–187 (2015).
38. H. E. Vuong, E. Y. Hsiao, Emerging roles for the gut microbiome in autism spectrum
disorder. Biol. Psychiatry 81, 411–423 (2017).
39. F. Liu et al., Altered composition and function of intestinal microbiota in autism
spectrum disorders: A systematic review. Transl. Psychiatry 9, 43 (2019).
40. M. Xu, X. Xu, J. Li, F. Li, Association between gut microbiota and autism spectrum
disorder: A systematic review and meta-analysis. Front. Psychiatry 10, 473 (2019).
41. T. E. Rose et al., 1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine
soluble epoxide hydrolase: Structure-activity relationships, pharmacokinetics, and
reduction of inflammatory pain. J. Med. Chem. 53, 7067–7075 (2010).
42. A. I. Ostermann et al., Oral treatment of rodents with soluble epoxide hydrolase in-
hibitor 1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl)urea (TPPU): Bioavailability,
resulting drug levels and modulation of oxylipin pattern. Prostaglandins Other Lipid
Mediat. 121, 131–137 (2015).
43. H. Ji, L. Xu, Z. Wang, X. Fan, L. Wu, Differential microRNA expression in the prefrontal
cortex of mouse offspring induced by glyphosate exposure during pregnancy and
lactation. Exp. Ther. Med. 15, 2457–2467 (2018).
44. N. Yu et al., Circular RNA expression profiles in hippocampus from mice with perinatal
glyphosate exposure. Biochem. Biophys. Res. Commun. 501, 838–845 (2018).
45. G. M. Williams, R. Kroes, I. C. Munro, Safety evaluation and risk assessment of the
herbicide Roundup and its active ingredient, glyphosate, for humans. Regul. Toxicol.
Pharmacol. 31, 117–165 (2000).
46. K. M. Herrmann, L. M. Weaver, The shikimate pathway. Annu. Rev. Plant Physiol.
Plant Mol. Biol. 50, 473–503 (1999).
47. H. Maeda, N. Dudareva, The shikimate pathway and aromatic amino acid biosynthesis
in plants. Annu. Rev. Plant Biol. 63, 73–105 (2012).
48. A. Samsel, S. Seneff, Glyphosate’s suppression of cytochrome P450 enzymes and
amino acid biosynthesis by the gut microbiome: Pathways to modern diseases. En-
tropy 15, 1416–1463 (2013).
49. L. Rueda-Ruzafa, F. Cruz, P. Roman, D. Cardona, Gut microbiota and neurological
effects of glyphosate. Neurotoxicology 75, 1–8 (2019).
50. I. Argou-Cardozo, F. Zeidán-Chuliá, Clostridium bacteria and autism spectrum con-
ditions: A systematic review and hypothetical contribution of environmental glyph-
osate levels. Med. Sci. 6, 29 (2018).
51. L. Wang et al., Elevated fecal short chain fatty acid and ammonia concentrations in
children with autism spectrum disorder. Dig. Dis. Sci. 57, 2096–2102 (2012).
52. J. F. Cryan et al., The micribiota-gut-brain axis. Physiol. Rev. 99, 1877–2013 (2019).
53. E. Sherwin, S. R. Bordenstein, J. L. Quinn, T. G. Dinan, J. F. Cryan, Microbiota and the
social brain. Science 366, eaar2016 (2019).
26. K. Hashimoto, Soluble epoxide hydrolase: A new therapeutic target for depression.
Expert Opin. Ther. Targets 20, 1149–1151 (2016).
27. K. M. Wagner, C. B. McReynolds, W. K. Schmidt, B. D. Hammock, Soluble epoxide
hydrolase as a therapeutic target for pain, inflammatory and neurodegenerative
diseases. Pharmacol. Ther. 180, 62–76 (2017).
54. K. R. Solomon, Estimated exposure to glyphosate in humans via environmental, oc-
cupational, and dietary pathways: An updated review of the scientific literature. Pest
Manag. Sci., 10.1002/ps.5717 (2019).
28. W. Swardfager et al., Metabolic/inflammatory/vascular comorbidity in psychiatric
disorders; soluble epoxide hydrolase (sEH) as a possible new target. Neurosci. Biobehav.
Rev. 87, 56–66 (2018).
Pu et al.
PNAS Latest Articles
|
7 of 7